MARKET WIREReuters • 1h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
Why EVO Stock slipped -1.56% Today — RQD Quant Desk Flash
$1.58 -1.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.57
Evotec SE (EVO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $562.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on EVO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is EVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.58 (-1.56% 1D, market cap $562.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EVO ranks #343 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does EVO compare to DRUG and STTK in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $556.7M) and STTK (Shattuck Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $574.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for EVO?
▼
For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.57 (-0.47%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EVO)Realized 20D OHLCV Swing Band: ±7.3%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY EVO SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)
SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.7M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.37+3.6% Next Q
39
Q2 (-2Q)Grade D$1.42+7% Next Q
42
Q3 (-1Q)Grade D$1.52+3.9% Next Q
44
CurrentGrade D$1.58-5.9% Hist 90D α
47
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a EVO Turnaround Squeeze
While EVO currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.64) and Max Pain ($1.66) forces dealer call-delta covering toward $4.29.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EVO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EVO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EVO Stock slipped -1.56% Today — RQD Quant Desk Flash
Evotec SE (EVO) slipped -1.56% to $1.58, trading at 9% of its 52-week range ($1.33 – $4.09). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 9% of its 52-week range ($1.33 – $4.09) with RSI-14 at 51.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.3% around $1.58 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $15.7M annual free cash flow.
Live EVO Headlines & Catalysts
MARKET WIREReuters • 2h ago
Gold rises on softer oil; Markets parse Fed signals - ReutersGold rises on softer oil; Markets parse Fed signals Reuters
CATALYSTReuters • 4h ago
Indian shares rise on Iran war talks, Reliance earnings beat - ReutersIndian shares rise on Iran war talks, Reliance earnings beat Reuters
CATALYSTReuters • 7h ago
Bank of England poised to raise rates but may push back on bets for more - ReutersBank of England poised to raise rates but may push back on bets for more Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Oil prices ease 3% on optimism for Qatari-led talks on ending Iran war - ReutersOil prices ease 3% on optimism for Qatari-led talks on ending Iran war Reuters
MARKET WIREReuters • 9h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 11h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EVO)
- ✓Walkthrough of EVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.36%⚡ TESTING RESISTANCE
2026-11-02O $1.60H $1.60L $1.58C $1.58VOL 64.1K
RES: $1.58SUP: $1.17SMA50: $1.64SMA200: $2.51
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on EVO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EVO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EVO)
Health Care Rank #343 of 1016
⚔️ DRUG vs EVO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EVO vs. DRUG, STTK, NGNE, PBYI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Evotec SE (EVO) ranks #343 by composite RQD confidence (47/100, grade D) and #429 by equity capitalization ($562.1M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with EVO at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EVO
ACTIVE
Evotec SE | D | 47/100 | — | — | — | -1.56% | $562.1M | Benchmark Subject |
| DRUG Bright Minds Biosciences Inc. | D | 46/100 | — | — | — | +2.48% | $556.7M | /drug-vs-evo → |
| STTK Shattuck Labs Inc. | E | 31/100 | — | — | -35.0% | -1.46% | $574.1M | /sttk-vs-evo → |
| NGNE Neurogene Inc. | D | 44/100 | — | — | -35.0% | -5.26% | $576.7M | /ngne-vs-evo → |
| PBYI Puma Biotechnology Inc | B- | 71/100 | 17.5x | 74.5% | 29.3% | -0.75% | $544.1M | /pbyi-vs-evo → |
2. EVO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTEvotec SE (EVO) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $562.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. EVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.58 (-1.56% 1D, market cap $562.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EVO ranks #343 in composite RQD confidence.
How does EVO compare to DRUG and STTK in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $556.7M) and STTK (Shattuck Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $574.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EVO?
For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EVO trading relative to its 50-day, 200-day, and 52-week technical levels?
EVO last traded at $1.58 (-1.56% on volume of 64,146 shares), positioning the stock -3.66% below its 50-day simple moving average ($1.64) and -37.05% below its 200-day simple moving average ($2.51). Across its 52-week range of $1.33 to $4.09, EVO sits at the 9.1% percentile with a 14-day RSI of 51.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.3% ($1.46 to $1.70).
EVO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is EVO stock moving today?
Why EVO Stock slipped -1.56% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.